Welcure Drugs & Pharmaceuticals Limited has announced a significant business development with the execution of two new export sourcing contracts, collectively valued at ₹85.6 crore. This development was disclosed to BSE Limited in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
New Orders from Global Clients
The company has signed two export sourcing agreements with reputed international counterparties—Giant Exim and Ravina International. Both assignments involve the procurement and consolidation of mycorrhizal inoculants in bulk bags on an EXW (Ex Works) basis. Each contract is valued at approximately ₹42.8 crore, bringing the total to ₹85.6 crore.
These orders represent a strategic step forward in Welcure’s global operations, as the company continues to build its reputation as a reliable export sourcing partner in the agrochemical and pharmaceutical sectors.
Low-Risk, High-Margin Revenue Model
Welcure clarified that these orders will contribute to the company’s fee-based revenue. Importantly, the contracts involve no inventory or logistics risk to the company. Income will be generated in the form of commissions, recognized on the dispatch of each lot. This asset-light approach is expected to enhance the company’s margins during the current quarter.
Strong Outlook and Growth Potential
In addition to the confirmed contracts, Welcure is also in advanced negotiations with other international clients for similar export sourcing mandates. The company expects to finalize additional orders worth over ₹20 crore (₹200 million) within the ongoing quarter, pending standard commercial formalities.
This indicates a strong pipeline and reinforces Welcure’s position as a competitive player in the fee-based export sourcing segment.
Focus on Sustainable and Debt-Free Growth
Welcure emphasized that these transactions fall within its regular course of business and are not related-party deals. The company remains committed to expanding its export portfolio while maintaining a debt-free capital structure, a factor that adds financial stability and attractiveness to investors.
With this new milestone, Welcure Drugs & Pharmaceuticals Limited is well-positioned to capitalize on growing global demand while ensuring risk-managed, profitable growth. The company has promised to issue timely updates as new developments occur.
Did you find this article interesting?
Stay connected with our blog for more insights and updates. We’d love to hear your thoughts, questions, or feedback in the comments below!
Cyient Semiconductor and MIPS Partner for Next-Gen Custom Silicon Solutions
Regular insider buying reported in these shares. Does it give any signal to the investors ?
